Technology
Agetech World research and innovation round-up

We round up the latest news in agetech research and innovation, from a human trial in ‘reverse ageing’ to the launch of a domestic longevity pod.
Approval has been secured in the United States for the first human trial targeting ‘reverse ageing’.
Boston-based company Life Biosciences will shortly commence trials of its ER-100 treatment which aims to treat eye disease through reprogramming cells.
It will initially treat around a dozen patients with glaucomas – a condition where high pressure inside the eye damages the optic nerve.
Each patient will receive injections of three powerful genes into an eye in an attempt to restore host cells to a healthier state by resetting their epigenetic controls.
It is over 20 years since Dr Shinya Yamanaka’s Nobel Prize work was first able to convert adult cells into pluripotent stem cells.
This reverse cell-editing process allows the regenerated cells – just like those found in an early embryo – to develop into the different, specialised cell types.
This trial has been approved by the Food And Drug Administration (FDA) after initial trials on animals proved a success.
Michael Ringel, chief operating officer at Life Biosciences, said: “It’s an incredibly big deal for us as an industry.
“It’ll be the first time in human history, in the millennia of human history, of looking for something that rejuvenates … So watch this space.”
Inherited longevity
New research claims that longevity-inheritability accounts for around 50 per cent of human lifespan.
For many decades, scientists had rated genetics as being a relatively low factor in human lifespan – compared to other inherited traits – at between 10 per cent and 25 per cent.
However, this new study from the Israeli-based Weizmann Institute of Science, presents an entirely different picture.
Led by Ben Shenhar, a PhD student, from the lab of Prof Uri Alon of Weizmann’s Molecular Cell Biology Department, it analysed three large twin databases from Sweden and Denmark – including a dataset of twins who were raised apart.
The researchers showed that earlier heritability estimates were masked by high levels of extrinsic mortality, such as deaths caused by accidents, infections and environmental hazards.
Their findings are consistent with the heritability of other complex human traits and with findings from animal models.
“For many years, human lifespan was thought to be shaped almost entirely by non-genetic factors, which led to considerable skepticism about the role of genetics in ageing and about the feasibility of identifying genetic determinants of longevity,” said Shenhar.
“By contrast, if heritability is high, as we have shown, this creates an incentive to search for gene variants that extend lifespan, in order to understand the biology of aging and, potentially, to address it therapeutically.”
Longevity blood test
In just a few years a simple blood test should be sufficient to gauge one’s anticipated longevity, claims Dr Tan Min-Han, chief executive and medical director of Singapore and Californian-based firm Lucence.
Dr Tan believes people will be able to go to a clinic near them to take a simple blood test that can detect early signs of ageing.
The results could guide lifestyle changes, such as sleep, diet and exercise, to improve key biomarkers and slow physical decline.
Lucence was founded in 2016 as a spin-off from Singapore’s Agency for Science, Technology and Research. While incorporated and headquartered in Singapore, the company also maintains a co-headquarters in Palo Alto, California.
Since then, it has secured more than US$80m in equity funding, including US$20m in a 2019 funding round led by IHH Healthcare.
He said: “Blood tests are more acceptable and accessible as opposed to uncomfortable procedures like mammograms and colonoscopies. I believe that technology could make a lot of this better.
“Five years ago, being able to detect cancers from blood tests was science fiction. But now, we have made that a reality.”
Longevity pod
A domestic longevity pod known as the E-Salt Cabin has been launched by Eleve Health, a California-based wellness technology company
Roughly the size of a compact car – at just over eight and a half feet long – the pod combines four core therapies: halotherapy, red light therapy, oxygen delivery, and aromatherapy.
Halotherapy disperses a fine, mineral-rich mist designed to support respiratory health. Red light therapy stimulates cellular repair and regeneration. Oxygen delivery aims to improve circulation and energy levels. And custom essential oil blends add a sensory layer
The company says it can be used as a tool to ‘support circulation, clarity, and recovery within a residential setting’.
Eleve said: “The pod reflects a broader shift among ultra-high-net-worth homeowners, with wearable technology, circadian lighting, biophilic interiors, and curated soundscapes becoming standard.”
News
Radiology AI may improve workflows

Radiology AI may improve workflows and patient care, but the technology also brings challenges for radiology departments, research suggests.
A focus issue from the Journal of the American College of Radiology brings together invited research and reviews exploring how AI is being used across different practice types.
Barriers include insufficient infrastructure, strict institutional regulations and a lack of insurance reimbursement, all of which can hamper the integration of AI into routine clinical workflows.
Radiology, the branch of medicine that uses imaging such as X-rays and scans to diagnose and treat disease, is widely seen as one of the fields most likely to be reshaped by AI.
The research includes contributions arguing that workflow improvement is not simply a secondary benefit of AI, but a main determinant of whether a tool succeeds.
Gelareh Sadigh, associate editor for health services research at the Journal of the American College of Radiology, said: “When thoughtfully implemented, AI can complement human expertise and improve efficiency and patient care.
“Successful workflow optimisation requires the integration of AI technology into routine workflows.
“This can be hampered by insufficient infrastructure, strict institutional regulations, and lack of insurance reimbursement.
“Poor integration of AI may degrade workflows, satisfaction, and safety and perpetuate bias in healthcare.”
According to Dr Sadigh, the articles in the focus issue reflect a broader shift in radiology: workflow is not a secondary benefit of AI, but a key factor in whether a tool is successful.
If AI is going to meaningfully help radiology, it must make care delivery better and not more complicated.
Ruth C. Carlos, editor-in-chief of the Journal of the American College of Radiology, said: “This focus issue provides meaningful signposts for AI effectiveness as we navigate a rapidly shifting landscape.”
News
AI system could help identify Alzheimer’s earlier

An AI tool could help identify Alzheimer’s disease around two years earlier by analysing signals already recorded in patients’ clinical records.
DementAI, a prototype developed by consultancy Katalyze Data, analyses existing medical record data to flag patients who may show early signs of the condition but have not yet been referred for specialist assessment.
Built as an end-to-end working prototype, the system connects stages clinicians often manage separately, from analysing medical records to applying models within decision pathways.
It is designed to work using information healthcare providers already hold, turning fragmented data into actionable insight without adding new screening burdens.
The system combines structured medical records, brain activity data and unstructured clinical information, using synthetic data where appropriate to support development.
By blending these signals, it aims to detect subtle patterns of decline that may be difficult to identify during short consultations.
Tamás Bosznay, principal consultant at Katalyze Data, said: “We are in a race against time when it comes to dementia.
“Early identification can make a meaningful difference to how patients and families experience the condition.
“But without better ways of finding people sooner, those opportunities can be lost.
“We didn’t build DementAI just to make predictions; we built it to buy patients time.
“By surfacing the signals already hiding in plain sight within clinical records, the system is designed to help ensure that when care teams are ready to act, the right patients are identified earlier and more consistently.”
DementAI was developed as part of the SAS Hackathon 2025, where it won the healthcare and life sciences category.
The team is now seeking engagement with NHS trusts to explore pilot deployments that could validate the model’s impact and support efforts to reduce delays in diagnosis.
Dr Iain Brown, global head of AI and data science at SAS, said: “Synthetic data, agentic AI concepts and governance are not ‘nice-to-haves’ in sensitive settings like healthcare.
“They are what make innovation usable at scale.
“DementAI shows how artificial intelligence can be applied in a way that is both ambitious and responsible.
News
Smart lights linked to fewer care home falls

AI smart lights in care homes were linked to up to 75 per cent fewer hospital visits after falls, according to an NHS evaluation.
The study examined 87 rooms across seven care homes providing residential, nursing, dementia and assisted living care.
Researchers compared six months of baseline data with six months after installing Nobi Smart Lights, AI-enabled ceiling-mounted devices designed to detect falls and alert staff within seconds.
The lights also turn on automatically when residents get out of bed, helping reduce the risk of night-time falls. Some homes reported zero fall-related hospital admissions during the evaluation period, while ambulance call-outs fell by up to 65 per cent.
Staff reported greater confidence when responding to unwitnessed incidents and said they spent less time reconstructing events or completing documentation.
Better visibility also helped staff distinguish genuine falls from controlled descents, where someone lowers themselves to the floor intentionally or slowly, allowing more incidents to be managed safely inside the care home.
The evaluation was carried out by the Suffolk and North East Essex Integrated Care Board.
“The Nobi light gives me peace of mind because Mum does fall a lot,” said the daughter of a resident at a participating Suffolk care home.
“I felt guilty about her going into a home, but now I know staff are alerted instantly and can be there straight away.”
The work formed part of the Integrated Care Board’s Digitising Social Care Programme, which supports care providers to adopt digital tools.
Implementation was delivered in partnership with Porters Care, one of Nobi’s UK partners, with support from Suffolk County Council and participating care providers.
Using NHS reference costs, the evaluation estimated £89,000 in avoided emergency care costs over six months, equivalent to a projected return on investment of around 196 per cent over three years.
Roeland Pilgrims, chief executive and co-founder of Nobi, said: “This independent NHS evaluation shows how intelligent care technology can deliver measurable improvements for residents, care teams and the wider health system.
“By giving staff timely, reliable insight, we can help reduce avoidable hospital admissions while improving safety, dignity and peace of mind.”
David Knowles, managing director of Porters Care, added: “These findings show the real-world impact of smart technology in care homes.
“By improving how falls are detected and understood, Nobi helps teams make clearer decisions and avoid unnecessary hospital admissions, while keeping residents safe.”
Further independent NHS-led evaluations are underway in other regions of the UK.
Research2 weeks agoInterview: The US company appealing Europe’s rejection of daily Alzheimer’s pill
News4 weeks agoLongevity startup Biopeak raises US$2.7m
News4 weeks agoBryan Johnson launches US$1m longevity programme
News4 weeks agoAgetech investment & innovation round-up
News2 weeks agoCentenarians’ blood reveals longevity clues
Wellness4 weeks agoInterview: Dr Matthew Bennett on building resilience and a pain-free healthspan
News4 weeks agoRe:Cognition and Cera expand Alzheimer’s clinical trials access
News4 weeks agoFrench biotech raises €12m for osteoarthritis trial















